Primary hyperaldosteronism, a common cause of resistant hypertension and an underlying cause of cardiac and renal diseases, is usually treated with mineralocorticoid receptor (MR) antagonists (Awosika et al., 2023; Miguel et al., 2024; Verma et al., 2024). This evidence concerns the gene NR3C2 and Primary hyperaldosteronism.